ImmunityBio opened lower at $8.48, compared with its previous close of $8.74. In the last trading session, the stock traded between $8.16 and $8.73. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in ImmunityBio is now worth
$ 105.20
giving a profit of
$ 5.20 (5.20%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.50 (-5.76%)
Day High
$8.73
Day Low
$8.16
Day Open
$8.48
Prev Close
$8.74
Volume
45,18,820
1W Return
-0.91%
1M Return
-6.73%
3M Return
20.51%
6M Return
18.35%
1Y Return
240.37%
Fundamentals
Market Cap ($ Mn)
8,730
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-65.84%
EPS (TTM)
$-0.22
Investment Returns
1 Week
-0.91%
1 Month
-6.73%
3 Months
20.51%
6 Months
18.35%
9 Months
39.37%
Financials
Quarterly
All values in $ Mn
7.6
Dec 24
16.5
Mar 25
26.4
Jun 25
32.1
Sep 25
38.3
Dec 25
51.2
Jun 26
Updates
21Oct
ImmunityBio locks QUILT-2.005 data, targets November topline results
Database lock completed for Cohort A of QUILT-2.005 trial involving 366 patients. Topline results for ANKTIVA plus BCG expected in November 2026. sBLA submission remains on track for fourth quarter of 2026. Trial evaluates first locally delivered, chemotherapy-free combination immunotherapy.
9 days ago
19Oct
ImmunityBio reports 71% complete response in bladder cancer trial
Phase 2/3 QUILT-3.032 study reports 71% complete response rate in BCG-unresponsive NMIBC. Median duration of complete response reached 26.6 months, with responses extending beyond 53 months. Cystectomy-free survival stood at 84% at 36 months, addressing key unmet clinical need. FDA expanded Anktiva indication in October 2026 to include papillary-only disease.
11 days ago
2Oct
ImmunityBio shares jump 10.78% as stock breaks recent resistance levels
Shares rose 10.78% to $10.28 on Friday. Stock jumped from $8.25 to $10.12 in two days. Previous rising floor pattern was broken by sharp spike. No specific news catalyst identified for the move.
27 days ago
31Jul
ImmunityBio secures UAE approval for ANKTIVA in bladder and lung cancer
ImmunityBio Inc. announced UAE approval for ANKTIVA in two cancer indications, supported by robust clinical trial data showing high response rates in bladder cancer and improved survival in lung cancer patients.
